182 related articles for article (PubMed ID: 33455487)
1. Use of Cost-Effectiveness Analyses for Decisions About Vaccination Programs for Meningococcal Disease in the United States, United Kingdom, The Netherlands, and Canada.
Huang L; Mauskopf J; Farkouh R; Masaquel C
Expert Rev Vaccines; 2021 Jan; 20(1):59-72. PubMed ID: 33455487
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
Si S; Zomer E; Fletcher S; Lee J; Liew D
Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
[TBL] [Abstract][Full Text] [Related]
3. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.
Welte R; Trotter CL; Edmunds WJ; Postma MJ; Beutels P
Pharmacoeconomics; 2005; 23(9):855-74. PubMed ID: 16153131
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.
De Wals P; Zhou Z
Pediatr Infect Dis J; 2017 Jul; 36(7):e203-e207. PubMed ID: 28027288
[TBL] [Abstract][Full Text] [Related]
5. Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.
Tin Tin Htar M; Jackson S; Balmer P; Serra LC; Vyse A; Slack M; Riera-Montes M; Swerdlow DL; Findlow J
BMC Public Health; 2020 Dec; 20(1):1890. PubMed ID: 33298015
[TBL] [Abstract][Full Text] [Related]
6. Global practices of meningococcal vaccine use and impact on invasive disease.
Ali A; Jafri RZ; Messonnier N; Tevi-Benissan C; Durrheim D; Eskola J; Fermon F; Klugman KP; Ramsay M; Sow S; Zhujun S; Bhutta Z; Abramson J
Pathog Glob Health; 2014 Jan; 108(1):11-20. PubMed ID: 24548156
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study.
Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T
PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884
[TBL] [Abstract][Full Text] [Related]
10. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
Burman C; Alderfer J; Snow VT
J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
[TBL] [Abstract][Full Text] [Related]
11. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine.
Keshavan P; Pellegrini M; Vadivelu-Pechai K; Nissen M
Expert Rev Vaccines; 2018 Oct; 17(10):865-880. PubMed ID: 30198805
[TBL] [Abstract][Full Text] [Related]
12. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
13. Evolving meningococcal immunization strategies.
Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
15. Challenges and opportunities for meningococcal vaccination in the developing world.
Shaker R; Fayad D; Dbaibo G
Hum Vaccin Immunother; 2018 May; 14(5):1084-1097. PubMed ID: 29393729
[TBL] [Abstract][Full Text] [Related]
16. Can we defeat meningococcal disease in low and middle income countries?
Greenwood B; Chiarot E; MacLennan CA; O'Ryan M
Vaccine; 2012 May; 30 Suppl 2():B63-6. PubMed ID: 22607901
[TBL] [Abstract][Full Text] [Related]
17. Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands.
Bousema JC; Ruitenberg J
Int J Health Policy Manag; 2015 Sep; 4(11):757-61. PubMed ID: 26673336
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of a single dose of the quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces.
Im JH; Woo H; Ha BM; Lee JS; Chung MH; Jung J
Vaccine; 2020 Jan; 38(4):730-732. PubMed ID: 31787413
[TBL] [Abstract][Full Text] [Related]
19. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.
Findlow J; Nuttens C; Kriz P
Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease.
Beck E; Klint J; Neine M; Garcia S; Meszaros K
Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
